Psomagen, Inc. has partnered with OlinkProteomics, which offers an innovative DNA-coupled immunoassay that identifies and quantifies protein biomarkers in clinical samples. The partnership enables end-to-end multi-omics clinical studies, a step that will enable a whole new generation of precision therapies derived from a more robust knowledge of human biology. Olink?s technology ? called the Proximity Extension Assay (PEA) ? uses antibodies with DNA tags that when hybridized with extremely high specificity, can measure the protein profile in patient samples using next-generation sequencing and qPCR. Psomagen?s 17-year history as a genomic sequencing and data analysis service provider makes it uniquely qualified to help drug developers add proteomics to their research strategies in this capacity. The improved dynamic range and exceptional readout specificity of Olink?s DNA-based assays have revolutionized multi-omics clinical research, delivering a deeper understanding of complex human biology and making new discoveries possible.